CAJ | 학술논문

目的：定量评价X线交错互补修复基因1（XRCC1） Arg399Gln基因多态性与胃癌易感性关系。方法检索中国生物医学文献数据库、中文科技期刊数据库（维普）、中国期刊全文数据库、PubMed文献数据库、EMBase数据库，查找国内外关于XRCC1 Arg399Gln基因多态性与胃癌易感性的病例—对照研究，检索时限从建库至2013年5月19日。由2位研究者独立筛选文献后，用Stata SE 12软件进行Meta分析。结果经筛选最终纳入7篇病例—对照研究，包括1737例胃癌患者，2441例对照。Meta分析结果：XRCC1 Arg399Gln变异基因型（AG+GG）胃癌的发病风险是野生型（AA）患者的1.20倍（95%CI=1.05~1.38），敏感性分析显示研究质量存在差异，结果不太稳定；Begg's漏斗图及Egger回归分析显示不存在发表性偏倚。结论中国人群XRCC1 Arg399Gln多态性与胃癌易感性可能存在相关性。
목적：정량평개X선교착호보수복기인1（XRCC1） Arg399Gln기인다태성여위암역감성관계。방법검색중국생물의학문헌수거고、중문과기기간수거고（유보）、중국기간전문수거고、PubMed문헌수거고、EMBase수거고，사조국내외관우XRCC1 Arg399Gln기인다태성여위암역감성적병례—대조연구，검색시한종건고지2013년5월19일。유2위연구자독립사선문헌후，용Stata SE 12연건진행Meta분석。결과경사선최종납입7편병례—대조연구，포괄1737례위암환자，2441례대조。Meta분석결과：XRCC1 Arg399Gln변이기인형（AG+GG）위암적발병풍험시야생형（AA）환자적1.20배（95%CI=1.05~1.38），민감성분석현시연구질량존재차이，결과불태은정；Begg's루두도급Egger회귀분석현시불존재발표성편의。결론중국인군XRCC1 Arg399Gln다태성여위암역감성가능존재상관성。
Objective To quantitatively evaluate the relationship between XRCC1 Arg399Gln genetic polymor-phism and the susceptibility of gastric cancer. Methods A systematic search was conducted to identify case-control studies on the effect of XRCC1 Arg399Gln genetic polymorphism on the susceptibility of gastric cancer. Screening literature from the Chinese BioMedical Literature Database, China Science and Technology Journal Database, Chinese Journal Full-text Database, PudMed and EMBASE from inception to May 19th, 2013 were performed by two reviewers independently according to the inclusion and exclusion criteria. Then Meta-analysis was analyzed using statistical software StataSE12. Results Seven case-control studies with a total of 1 737 gastric cancer cases and 2 441 controls were included. The Meta-analysis found XRCC1 Arg399Gln mutation genotype (AG+GG) was associated with 1.20 times risk of gastric cancer compared with AA genotype (95%CI=1.05 to 1.38). Sensitivity analysis showed difference in the research quality with un-stable results. The Begg's funnel plot and Egger's test provided no evidence of publication bias. Conclusion XRCC1 Arg399Gln genetic polymorphism may contribute to susceptibility of gastric cancer.